Biopool International (Canada) acquires heparin-induced thrombocytopenia (HIT) test
This article was originally published in Clinica
Biopool International (Canada) has acquired a technology for the early detection of heparin-induced thrombocytopenia (HIT), a potentially fatal complication that can occur in 6-10% of patients treated with the drug. Biopool will manufacture and market the test kit, which provides results within one hour. Sales outside the US are expected to start in early 1996, and an application for FDA approval will be filed in the first half of the year.